Bharat Biotech Chief Dr Krishna M Ella named as new President of Indian Vaccine Manufacturers Association

Published On 2024-05-01 10:30 GMT | Update On 2024-05-01 10:30 GMT

Hyderabad: The Indian Vaccine Manufacturers Association (IVMA) has announced Dr Krishna M Ella, a distinguished scientist and successful entrepreneur, as the association’s new President for a two-year period from April 2024-2026.

Dr. Ella takes over the Presidency from Mr. Adar C Poonawala who held the post from 2019 to March 2024. For the current 2-year term, Ms. Mahima Datla, Managing Director of Biological E assumes the role of Vice President, Mr. T. Srinivas, CFO of Bharat Biotech, will be Treasurer and Dr. Harshavardhan, will continue as Director General of IVMA.

"Vaccines are the vital pillar of global health, and the IVMA mission is to ensure that every individual, regardless of where they live, has access to life-saving immunizations," Dr. Krishna M Ella, President of IVMA stated. "Innovation, sustainability, and equity are the foundations of our collective vision, and I am pleased to serve IVMA along with its distinguished members and contribute to its vision to protect and enhance public health in India and the Developing World."

He emphasized the need to support African nations' public health vision by IVMA members and also urged to formulate policies and regulations in line with WHO and USFDA, which will help the industry to be not only globally competitive but also fortify India’s vision to boost the level playing field world-over in preventive care.

His appointment comes at a critical time when the world is grappling with emerging infectious diseases and the need for preventative vaccine research and development, and access to safe and affordable vaccines, is more pressing than ever.

Under Dr. Ellas's leadership, the IVMA aims to fortify collaboration between vaccine manufacturers, researchers, and policymakers to accelerate the development of new vaccines and improve production processes. Most importantly fosters the growth of startups, industry-academia, as well as Public-Private- Partnerships.

“Dr. Ella’s expertise and entrepreneurial spirit are exactly what the vaccine industry needs to navigate the complex challenges of the 21st century." Dr. Harshavardhan, Director General, IVMA said.

"His commitment to innovation and global health equity is well known, and it will undoubtedly help lead the industry in bringing transformative advancements in vaccine innovation, research, and manufacturing capabilities of India." Dr. Harshavardhan added.

The IVMA, with Dr. Ella at the forefront, aims to be more responsive to the needs of a rapidly changing world. His leadership signifies a key phase for the Association and its collective voice, one that is marked by the desire to excel and a deep commitment to humanity's well-being.

"IVMA's mission is to bring to the fore the Indian private-sector human vaccine manufacturer’s concerns related to the progress and profitability of the industry and in streamlining regulatory pathways and matters related to audits and inspections in consultations with the national Central Drugs Standard and Control Organization.

Furthermore, IVMA and its Members will strive to maintain and improve upon its status as the Global Hub for vaccines of quality at affordable cost. As demonstrated during the COVID-19 pandemic, Members of IVMA are ready to take on the challenges of the emerging new pathogens and ensure protection from future pandemics," the release stated.

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Bharat Biotech Chief Dr Krishna M Ella named as new President of Indian Vaccine Manufacturers Association

Similar News

GSK Blenrep combos approved in EU for treatment of relapsed/refractory multiple myeloma

NPPA Warns Drugmakers Against Arbitrary Pricing, Calls for MRP Uniformity

NPPA Committee Asks Intas to Clarify Patent Discrepancy in Clozapine ER Pricing Plea

India Cuts API Imports, Disburses Rs 1,008 Cr Under PLI Schemes, Parliament Told

PCI President Montu Patel granted pre-arrest bail in corruption case

Alembic Pharma gets USFDA nod for anticonvulsant drug Carbamazepine Extended Release

Licences of 2 pharma stores suspended for unethical trade practices

16912 Jan Aushadhi Kendras opened till June 30: Minister